Thermo Fisher Scientific Inc (TMO) Financial Statements

Thermo Fisher Scientific Inc

TMO · NYSE

	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
Total Revenue	$44.56B	$42.88B	$42.86B	$44.91B	$39.21B	$32.22B	$25.54B	$24.36B
Research & Development	$1.40B	$1.39B	$1.34B	$1.47B	$1.41B	$1.18B	$1.00B	$967.00M
Selling, General & Administrative	$8.73B	$8.60B	$8.45B	$8.99B	$8.01B	$6.93B	$6.14B	$6.06B
Operating Expenses	$36.81B	$35.54B	$36.00B	$36.52B	$29.18B	$24.42B	$20.95B	$20.57B
Operating Income	$7.75B	$7.34B	$6.86B	$8.39B	$10.03B	$7.79B	$4.59B	$3.78B
Interest Expense	—	—	$1.38B	$726.00M	$536.00M	$553.00M	$676.00M	$667.00M
Other Income / (Expense)	-$12.00M	$12.00M	-$65.00M	-$104.00M	-$694.00M	-$76.00M	-$70.00M	$9.00M
Income Before Taxes	$7.31B	$7.04B	$6.30B	$7.83B	$8.84B	$7.22B	$4.07B	$3.26B
Provision for Income Taxes	$547.00M	$657.00M	$284.00M	$703.00M	$1.11B	$850.00M	$374.00M	$324.00M
Net Income	$6.72B	$6.34B	$5.96B	$6.96B	$7.73B	$6.38B	$3.70B	—
Basic EPS	$17.77	$16.58	$15.52	$17.75	$19.62	$16.09	$9.24	$7.31
Diluted EPS	$17.74	$16.53	$15.45	$17.63	$19.46	$15.96	$9.17	$7.24
Basic Shares Outstanding	377.00M	382.00M	386.00M	392.00M	394.00M	396.00M	400.00M	402.00M
Diluted Shares Outstanding	378.00M	383.00M	388.00M	394.00M	397.00M	399.00M	403.00M	406.00M

Analyst Estimates

Period	Consensus EPS	Low	High	Estimates	Revisions
Dec 2026	$25.12	$25.01	$25.21	12	↑10 ↓0
Dec 2027	$27.51	$26.49	$29.07	12	↑9 ↓2
Dec 2028	$30.01	$28.83	$31.71	6	↑2 ↓0
Dec 2029	$34.22	$34.22	$34.22	1	↑0 ↓0

Forward estimates are the sell-side consensus reported by Nasdaq, not a metir forecast.

Symbol: TMO
Type: Stock
Sector: Industrials
Industry: Industrial Machinery/Components
Country: North America
Exchange: NYSE

Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $45 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Gibco, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.

Key Issues

Bullish view

Thermo Fisher is expanding bioproduction capabilities, and the supplied evidence identifies stronger demand as a driver of its raised 2026 outlook. Continued biopharmaceutical activity could support instruments, consumables and services.

Bearish view

Competition is intensifying, and the evidence specifically flags execution as a key requirement. If customers delay production investment or Thermo Fisher executes poorly, bioproduction growth may not sustain momentum.

Analyst Consensus

See all

Buy

21 analysts

$577

Current

—

Low

$630

Average

—

High

Average target implies +9.17% versus the current price.

Earnings History

BeatMissNo estimate

Peers

Eaton Corporation, PLC Ordinary SharesETN · NYSE$449.37